medigraphic.com
ISSN 1561-2988 (Print)

2021, Number 2

<< Back Next >>

Rev Cubana Farm 2021; 54 (2)

Characterization of the list of medicines of the National Hospital of Obstetrics and Gynecology in Vietnam

Vu HPA, García FA

Language: Spanish
References: 26
Page: 1-15
PDF size: 825.02 Kb.


ABSTRACT

Introduction: It is a key tool to guarantee the proper functioning of a hospital to have a safe and effective list of medicines.
Objective: Characterize the list of medicines used in the National Hospital of Obstetrics and Gynecoloy of Vietnam in 2018.
Methods: It was conducted a descriptive study that included the number of medicines, their financing, the therapeutic group, the classification of high, medium or low expense, or vital, essential and not-essential; and the matrix in these two axes.
Results: The list of medicines had 249 products. The group of antibiotics and drugs for the control of infections was the most frequent, being a 16,14% of the total of medicines. More than half of the expenditure in medicines (VND 134 779 395 936,88) was financed by the National Medical Insurance. 26 medicines, mainly hormones treatments, were financed by the patients. Among the drugs of higher cost, there were four non-essential ones that require a review.
Conclusions: The list of medicines of the hospital is formed by a large number of therapeutic groups. The matrix analysis allows identifying the medicines to assess in the next process of updating of the list, as well as those that need a more frequent control.


REFERENCES

  1. Holloway K, Green T. Drugs and Therapeutics Committee - A Practical Guide.Geneva: Word Health Organization; 2004. [acceso 20/05/2021]. Disponible en:https://apps.who.int/iris/handle/10665/68553?show=full

  2. Melendez H, Lambis WE. Análisis y diseño de un sistema de gestión deinventario para la farmacia de la Fundación Madre Herlinda Moises, basado enuna categorización multicriterio ABC/VEN [Tesis]. [Cartagenas]: Universidad deCartagena; 2013.

  3. Pirankar SB, Ferreira AM, Vaz F, Pereira-Antao I, Pinto N R, Perni SG.Application of ABC-VED analysis in the medical stores of a tertiary care hospital.International Journal of Pharmacology & Toxicology. 2014 [acceso 20/05/2021];4.Disponible en: https://pubmed.ncbi.nlm.nih.gov/25609859/

  4. Sefnew M A. Special and Aid Pharmaceuticals ABC-VEN Matrix Analysis of TikurAnbessa Specialized Hospital for the Years 2009 to 2013, Addis Ababa, Ethiopia.Indian Journal of Basic and Applied Medical Research. 2017 [acceso20/05/2021];6 Disponible en:https://www.ijbamr.com/assets/images/issues/pdf/March%202017%20669-681.pdf

  5. Yevstigneev SV, Titarenko AF, Abakumova T, Alexandrova EG, KhaziakhmetovaV, Ziganshina LE. Towards the rational use of medicines. International Journal ofRisk & Safety in Medicine. 2015 [acceso 03/02/2021];27. Disponible en:https://content.iospress.com/articles/international-journal-of-risk-and-safetyin-medicine/jrs690

  6. Güner Gören H, Dağdeviren O. An Excel-Based Inventory Control System Basedon ABC and VED Analyses for Pharmacy: A Case Study. Galore InternationalJournal of Health Sciences and Research. 2017 [acceso 18/01/2021];2.Disponible en: https://www.gijhsr.com/GIJHSR_Vol.2_Issue.1_March2017/3.pdf

  7. Biruk WT, Ayalewu AW, Mulugeta AA, Mende M, Bisrat G G, Anidinet AH. ABCVENMatriz Analysis of the Pharmacy Store in a Secondary Level Health Care Facility in Arbaminch Town, Southern Ethiopia. J Young Pharm. 2019 [acceso18/01/2021];11. Disponible en: http://www.jyoungpharm.org/article/1314

  8. The Ministry of Health. Circular. Prescribing organization and operation of thedrug and treatment council in hospitals. Hanoi: The Ministry of Health; 2013.[acceso 18/01/2021]. Disponible en: https://vanbanphapluat.co/circular-no-21-2013-tt-byt-the-drug-and-treatment-council-in-hospitals

  9. Huong VT. Evaluación de las actividades del Consejo farmacoterapéutico paradesarrollar e implementar la Lista de medicamentos en algunos hospitalesgenerales [Tesis doctoral de Farmacología]. [Hanoi]: Universidad de Farmacia deHanoi; 2012.

  10. Dang HQ. Análisis de la estructura del consumo de medicamentos en Hospital87- Departamento General de Logística 2006-2008 [Tesis de Maestría]. [Hanoi]:Universidad de Farmacia de Hanoi; 2009.

  11. Trung HH. Investigación sobre algunas soluciones para mejorar la calidad delsuministro de medicamentos en el Hospital Popular 115 [Tesis Doctoral]. Hanoi:Universidad de Farmacia de Hanoi; 2012.

  12. Nguyet Giao CT. Análisis de la situación del uso de medicamentos en elHospital Pediátrico Nghe An; 2016 [Tesis del Especialista Farmacéutico II].[Hanoi]: Universidad de Farmacia de Hanoi; 2017.

  13. 13.Thanh Ha TT. Análisis de la situación del uso de medicamentos en el HospitalNacional de Obstetricia y Ginecología 2014 [Tesis del Especialista en FarmaciaII]. [Hanoi]: Universidad de Farmacia de Hanoi; 2016.

  14. Huyen LT. Análisis de la lista de medicamentos utilizados en el HospitalNacional de Obstetricia y Ginecología en 2017 [Tesis de Maestría enFarmacología]. [Hanoi]: Universidad de Farmacia de Hanoi; 2019.

  15. Departamento de Administración de Medicamentos. Lista de medicamentosde marca originales de la fase 1 hasta la 19. Vietnam: Ministerio de SaludPública; 2019 Disponible en: http://www.dav.gov.vn

  16. Montes-Vera MR, Garrido-Acosta O, Anguiano-Robledo L, Sánchez-NavarreteJ, Pérez-Cruz E, Rodríguez-Wong U, Cruz-Rico J, et al. Aspectosfarmacocinéticos de bevacizumab. Rev Hosp Jua Mex. 2013 [acceso09/05/2021];80. Disponible en: https://www.medigraphic.com/pdfs/juarez/ju-2013/ju131l.pdf

  17. Agencia Europea de Medicamentos. Ficha técnica de Aloxi®. Amsterdam:EMA; 2018. Disponible en:https://www.ema.europa.eu/en/medicines/human/EPAR/aloxi

  18. Ngoc SH. Análisis de la lista de medicamentos utilizados en el HospitalPediátrico Ninh Binh en 2016 [Tesis]. [Hanoi]: Universidad de Farmacia de Hanoi;2016

  19. Laboratorio Pfzier. Ficha técnica Unasyn® 1,5g. New York: Pfizer; 2019[acceso 18/01/2021]. Disponible en:http://labeling.pfizer.com/ShowLabeling.aspx?id=11230

  20. Ministerio de Sanidad, Política Social e Igualdad de España. Agencia españolade medicamentos y productos sanitarios. Ficha técnica de Curosurf 120 y 240.Madrid: Ministerio de Sanidad, Política Social e Igualdad de España; oct 2016.

  21. Navarro M B, Cruz M, Duvergel Y C, Navarro M. Principales factores de riesgode la morbilidad y mortalidad neonatales. MEDISAN. 2018 [acceso 14/06/2020];22. Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192018000700578

  22. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozed E, te Pas A, Plavka R, etal. European Consensus Guideline on the management of Respiratory DistressSymdrome – 2019 Update. Neonatology. 2019 [acceso 14/06/2020];115.Disponible en: https://www.karger.com/Article/Fulltext/499361

  23. Herrera AM, López-Delgado N. Estudio técnico de bevacizumab paracarcinoma in situ de la mama, parte no específica en el marco delprocedimiento técnico científico y participativo de exclusiones. Instituto deEvaluación Tecnológicas en Salud; 2018.

  24. Ismael JC, Diaz MC, Pesce V. Drogas de alto costo en el tratamiento delcáncer de mama avanzado no terapias antiHER2. Guía de pŕactica Clínica.Ciudad Autónoma de Buenos Aires: Instituto Nacional del Cáncer; 2015.Disponible en: https://bancos.salud.gob.ar/recurso/cancer-de-mamametastasico-terapia-no-antiher2

  25. Parathoduvil A A, Sisupalan A, Rema P L. Comparison of AntiemeticEffectiveness of Palonosetron Versus Ondansetron in Patient on CancerChemotherapy: A Prospective Observation Study in South Indians. J Clin DiagnRes. 2017 [acceso 14/06/2020];11. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483698/pdf/jcdr-11-FC10.pdf

  26. Young JN, Jang HL, Moon SP. Early prophylactic use of Curosurf versusNewfactan for respiratory distress syndrome in premature infants. Perinatology.2016 [acceso 08/10/2020];27. Disponible en:https://synapse.koreamed.org/articles/1071326




2020     |     www.medigraphic.com